APG777, Placebo
APG777-202
Phase 2 small_molecule active
Quick answer
APG777, Placebo for Atopic Dermatitis is a Phase 2 program (small_molecule) at Apogee Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Apogee Therapeutics
- Indication
- Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active